MedPath

Study the efficacy of phalatrikadi kwath in the management of non alcoholic fatty liver disease grade 1 and grade 2

Phase 2
Conditions
Health Condition 1: K759- Inflammatory liver disease, unspecified
Registration Number
CTRI/2023/05/053029
Lead Sponsor
TAPUBRATA BARUAH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Pain in the right upper quadrant/epigastric region,

2.Nausea

3.Vomiting

4.Loss of appetite

5.Burning sensation in abdomen

6.USG(whole abdomen) showing fatty infiltration of liver

7.Biochemical test,LFT findings

Exclusion Criteria

1.Viral hepatitis

2.Autoimmune hepatitis

3.Wilson disease

4.Alfa 1 antitrypsin deficiency

5.Haemochromatosis

6.Alcoholic fatty liver

7.Pregnancy and lactation

8.Severe cardiac problem

9.Cancer patients

10.Psychiatric disorder

11.Stomach ulcer

12.Surgical interventions,if any

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The symptoms of fatty liver such as loss of appetite ,nausea,vomiting will subsideTimepoint: 30 days to 6 months
Secondary Outcome Measures
NameTimeMethod
The biochemical markers i.e. LFT,lipId profile will go to normal limitsTimepoint: 30 days to 6 months
© Copyright 2025. All Rights Reserved by MedPath